SNDX FY 2012 Earnings — Syndax Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

SNDXSyndax Pharmaceuticals, Inc.

$2B

FY 2012 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$9M

Net Income

-$10M

EPS (Diluted)

$-0.14

Cash Flow

Operating Cash Flow

-$9M

Free Cash Flow

-$9M

Stock-Based Comp.

$139,000

Balance Sheet

Total Assets

$2M

Total Liabilities

$31M

Stockholders' Equity

-$29M

Cash & Equivalents

$537,000

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	-$51,000	+100.0%
Operating Income	-$9M	-$10M	+9.2%
Net Income	-$10M	-$13M	+23.9%